Barbara Czako

Barbara Czako has a diverse work experience in the field of medicinal chemistry and research. Barbara is currently working at Nurix Therapeutics as the Director of Medicinal Chemistry, a role they started in June 2022. Prior to that, they worked as a Principal Scientist at Nurix Therapeutics from July 2021.

Before joining Nurix Therapeutics, Barbara worked at MD Anderson Cancer Center for several years. Barbara'sroles there included being a Principal Scientist from November 2019 to June 2021, a Senior Research Scientist from an unknown start date to November 2019, and a Co-Director of the Pharmaceutical Chemistry Facility from an unknown start date to 2018. As a Co-Director, they collaborated closely with MD Anderson investigators, providing them with the necessary tools and compounds for their biomedical research.

Barbara also had experience working at Merck & Co. as a Senior Research Chemist from an unknown start date to 2012. Prior to that, they were a Postdoctoral Fellow at Harvard University from November 2006 to April 2009, where they coauthored a book and conducted research on cortistatin analogs with potential anti-angiogenic activity. Barbara started their research career as a Graduate Student at the University of Pennsylvania from an unknown start date to 2006.

Overall, Barbara Czako's work experience highlights their expertise in medicinal chemistry, research, and collaboration with investigators in the field.

Barbara Czako earned their PhD in Synthetic Organic Chemistry from the University of Pennsylvania, where they studied from 2001 to 2006.